Backed by strong data and boasting a mechanism of action that avoids the opioid route, Zilretta (FX006, triamcinolone acetonide with a poly lactic-co-glycolic acid matrix) – the pain drug for osteoarthritis of the knee from Flexion Therapeutics Inc. – won FDA approval smack on its PDUFA date.